Russian Heart Failure Journal 2014year Pneumonia in hospitalized patients with circulatory decompensation (Pavlov Hospital Registry)

To access this material please log in or register

Register Authorize

Pneumonia in hospitalized patients with circulatory decompensation (Pavlov Hospital Registry)

Arutyunov A.G., Rylova A.K., Arutyunov G.P.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: circulatory decompensation, pneumonia, register

DOI: 10.18087 / rhfj.2014.3.1955

Background. Universal ageing of the population, success of medicine in treatment of cardiovascular diseases, and prolonged life expectancy resulted in prevalence of patients with high comorbidity. A combination of two or more diseases, for example, CHF and pneumonia, considerably worsens the life prognosis. Aim. To study the effect of concurrent CHF and pneumonia on early and remote prognoses in real-life clinical practice. Materials and methods. Data of patients with decompensated CHF and pneumonia included in the Pavlov Hospital Registry were analyzed. Results. Pneumonia was diagnosed in 317 CHF patients. 301 patients had community-acquired pneumonia and 16 patients had nosocomial pneumonia; women were diagnosed with pneumonia twice as frequently as men. A considerable proportion of patients had no typical signs of pneumonia onset, such as leukocytosis and fever, and severity of the condition was primarily determined by pronounced comorbidities. The death rate of patients with pneumonia was 45.7% for one year. The highest risk of fatal outcome was associated with the following phenotypes: pneumonia + chronic kidney disease (CKD), pneumonia + anemia + CKD, pneumonia + lean body mass deficiency, pneumonia + changed antibacterial therapy. Conclusion. In patients with circulatory decompensation, pneumonia is always severe; it aggravates CHF, and considerably increases the risk of fatal outcome.
  1. Klein L, Grau-Sepulveda MV, Bonow RO et al. Quality of care and outcomes in women hospitalized for heart failure. Circ Heart Fail. 2011 Sep;4 (5):589–98.
  2. Goyal A, Norton CR, Thomas TN et al. Predictors of incident heart failure in a large insured population: a one million person-year follow-up study. Circ Heart Fail. 2010 Nov;3 (6):698–705.
  3. Чучалин А. Г., Цой А. Н., Архипов В. В. Диагностика и лечение пневмоний с позиции медицины доказательств. Consilium medicum. 2002;4:620–650.
  4. Яковлев С. В. Современое значение фторхинолонов в антимикробной химиотерапии. Кремлевская медицина, Клинический вестник. 2001;1:20–24.
  5. Capelastegui A, España PP, Bilbao A et al. Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care. J Infect. 2010 Nov;61 (5):364–71.
  6. Brar NK, Niederman MS. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis. 2011 Feb;5 (1):61–78.
  7. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012 Jan;67 (1):71–9.
  8. Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med. 2009 Apr;30 (2):127–35.
  9. Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. Med Clin North Am. 2011 Nov;95 (6):1143–61.
  10. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America / American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 (Suppl 2):S27–72.
  11. Kaplan V, Clermont G, Griffin MF et al. Pneumonia: still the old man's friend? Arch Intern Med. 2003 Feb 10;163 (3):317–23.
  12. Lee DS, Gona P, Albano I et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail. 2011 Jan;4 (1):36–43.
  13. Lee DS, Schull MJ, Alter DA et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail. 2010 Mar;3 (2):228–35.
  14. Dieplinger B, Gegenhuber A, Kaar G et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem. 2010 Jun;43 (9):714–9.
  15. Ghali JK, Kadakia S, Cooper R et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med. 1988;148 (9):2013–2016.
  16. Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health. 1997;87 (4):643–648.
  17. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80 (5):437–441.
  18. Jackson ML, Neuzil KM, Thompson WW et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004 Dec 1;39 (11):1642–50.
  19. Kaplan V, Angus DC, Griffin MF et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002 Mar 15;165 (6):766–72.
  20. O'Meara ES, White M, Siscovick DS et al. Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, morta­lity, and influence on longer-term survival. J Am Geriatr Soc. 2005 Jul;53 (7):1108–16.
  21. Thomsen RW, Riis A, Nørgaard M et al. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10‑year population-based study in Denmark. J Intern Med. 2006 Apr;259 (4):410–7.
  22. Fry AM, Shay DK, Holman RC et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002. JAMA. 2005 Dec 7;294 (21):2712–9.
  23. Oosterheert JJ, Bonten MJ, Hak E et al. The increase in pneumonia-related morbidity and mortality among adults in the Netherlands and possible explanations for it. Ned Tijdschr Geneeskd. 2004 Sep 4;148 (36):1765–9.
  24. LaCroix AZ, Lipson S, Miles TP, White L. Prospective study of pneumonia hospitalizations and mortality of U. S. older people: the role of chronic conditions, health behaviors, and nutritional status. Public Health Rep. 1989 Jul-Aug;104 (4):350–60.
  25. Thomsen RW, Kasatpibal N, Riis A et al. The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. J Gen Intern Med. 2008 Sep;23 (9):1407–13.
  26. Klare B, Kubini R, Ewig S. Risk factors for pneumonia in patients with cardiovascular diseases. Pneumologie 2002;56 (12):781–8.
  27. McAlister FA, Majumdar SR, Blitz S et al. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005 Apr;28 (4):810–5.
  28. Lee DS, Austin PC, Rouleau JL et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003 Nov 19;290 (19):2581–7.
  29. Calvillo-King L, Arnold D, Eubank KJ, Lo M et al. Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: systematic review. J Gen Intern Med. 2013 Feb;28 (2):269–82.
  30. Mortensen EM, Coley CM, Singer DE et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002 May 13;162 (9):1059–64.
  31. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010 Feb;10 (2):83–92.
  32. Corrales-Medina VF, Suh KN, Rose G et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011 Jun;8 (6):e1001048.
  33. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58 (5):377–82.
  34. Howell MD, Donnino MW, Talmor D et al. Performance of severity of illness scoring systems in emergency department patients with infection. Acad Emerg Med. 2007 Aug;14 (8):709–14.
  35. Lim WS, Macfarlane JT, Boswell TC et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001 Apr;56 (4):296–301.
  36. British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001 Dec;56 (Suppl 4):IV1–64.
  37. Charles PG, Wolfe R, Whitby M et al. SMART-COP: a tool for predic­ting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008 Aug 1;47 (3):375–84.
  38. España PP, Capelastegui A, Gorordo I et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006 Dec 1;174 (11):1249–56.
  39. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996 Jan 10;275 (2):134–41.
  40. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med. 2005 Dec 29;353 (26):2788–96.
  41. Tleyjeh IM, Kashour T, Hakim FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med. 2009 Oct 12;169 (18):1658–67.
  42. van den Hoek HL, Bos WJ, de Boer A, van de Garde EM. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ. 2011 Nov 29;343: d7281.
  43. Nakayama K, Sekizawa K, Sasaki H. ACE inhibitor and swallowing reflex. Chest. 1998 May;113 (5):1425.
  44. El Solh AA, Saliba R. Pharmacologic prevention of aspiration pneumonia: a systematic review.
  45. Rafailidis PI, Matthaiou DK, Varbobitis I, Falagas ME. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol. 2008 Jun;64 (6):565–73.
  46. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012 Jul 11;345: e4260.
  47. van de Garde EM, Souverein PC, van den Bosch JM et al. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J. 2006 Jun;27 (6):1217–22.
  48. Etminan M, Zhang B, Fitzgerald M, Brophy JM. Do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study. Pharmacotherapy. 2006 Apr;26 (4):479–82.
  49. Raut M, Schein J, Mody S et al. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Curr Med Res Opin. 2009 Sep;25 (9):2151–7.
  50. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010 Mar;122 (2):130–41.
  51. Lloyd-Jones D, Adams RJ, Brown TM et al. Executive summary: heart disease and stroke statistics-–2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23;121 (7):948–54.
  52. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007 Jul 15;45 (2):158–65.
  53. Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part 2: arterial pressure-flow and pressure-volume relations in humans. Hypertension. 2010 Oct;56 (4):563–70.
  54. Merkus D, Kajiya F, Vink H et al. Prolonged diastolic time fraction protects myocardial perfusion when coronary blood flow is reduced. Circulation. 1999 Jul 6;100 (1):75–81.
  55. Mavrogeni S, Manoussakis MN. Myocarditis as a complication of influenza A (H1N1): evaluation using cardiovascular magnetic re­sonance imaging. Hellenic J Cardiol. 2010 Jul-Aug;51 (4):379–80.
  56. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010 Jun 15;121 (23):2592–600.
  57. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J. 2008 Jan;29 (1):96–103.
  58. Smeeth L, Thomas SL, Hall AJ et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004 Dec 16;351 (25):2611–8.
  59. Ramirez J, Aliberti S, Mirsaeidi M et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008 Jul 15;47 (2):182–7.
  60. Yende S, D'Angelo G, Kellum JA et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008 Jun 1;177 (11):1242–7.
  61. Degraff AC, Travell JG, Yager JA. An electrocardiographic study of the heart in lobar pneumonia. J Clin Invest. 1931 Aug;10 (3):633–51.
  62. Morganroth J, Dimarco JP, Anzueto A et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest. 2005 Nov;128 (5):3398–406.
  63. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis. 2008 May;14 (5):727–33.
  64. Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest. 2003 Jul;124 (1):328–36.
  65. Chong CP, Street PR. Pneumonia in the elderly: a review of the epidemiology, pathogenesis, microbiology, and clinical features. South Med J. 2008 Nov;101 (11):1141–5.
  66. Palmer LB, Albulak K, Fields S et al. Oral clearance and pathogenic oropharyngeal colonization in the elderly. Am J Respir Crit Care Med. 2001 Aug 1;164 (3):464–8.
  67. Renshaw M, Rockwell J, Engleman C et al. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol. 2002 Nov 1;169 (9):4697–701.
  68. Kikuchi R, Watabe N, Konno T et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med. 1994 Jul;150 (1):251–3.
  69. Teramoto S, Fukuchi Y, Sasaki H et al. High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc. 2008 Mar;56 (3):577–9.
  70. Jackson ML, Nelson JC, Jackson LA. Risk factors for community-acquired pneumonia in immunocompetent seniors. J Am Geriatr Soc. 2009 May;57 (5):882–8.
  71. Loeb M, Neupane B, Walter SD et al. Environmental risk factors for community-acquired pneumonia hospitalization in older adults. J Am Geriatr Soc. 2009 Jun;57 (6):1036–40.
  72. Almirall J, Bolíbar I, Serra-Prat M et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008 Jun;31 (6):1274–84.
  73. Riquelme R, Torres A, el-Ebiary M et al. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med. 1997 Dec;156 (6):1908–14.
  74. Zalacain R, Torres A, Celis R et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J. 2003 Feb;21 (2):294–302.
  75. Metlay JP, Schulz R, Li YH et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med. 1997 Jul 14;157 (13):1453–9.
  76. Fernández-Sabé N, Carratalà J, Rosón B et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore). 2003 May;82 (3):159–69.
  77. Ahkee S, Srinath L, Ramirez J. Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leukocytosis. South Med J. 1997 Mar;90 (3):296–8.
  78. Kaplan V, Angus DC. Community acquired pneumonia in the elderly. Crit Care Clin. 2003 Oct;19 (4):729–48.
  79. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA. 1997 Nov 5;278 (17):1440–5.
  80. Mandell LA, Marrie TJ, Grossman RF et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis. 2000 Aug;31 (2):383–421.
  81. Чучалин А. Г., Синопальников А. И., Козлов Р. С. и др. Внебольнич­ная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. – М., 2010. – 106 с.
  82. Torres A, Menendez R, Wunderink R. Infectious disease of lung Murray and Nadel’s Textbook of Respiratory Medicine [Chapter: Pyogenic Bacterial Pneumonia and Lung Abscess]: vol. 1 / Mason RJ, Their SO, ed. 5th ed. – 2010: Philadelphia: Saunders. – P. 699–740.
  83. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009 Feb;103 (2):309–16.
  84. El-Solh AA, Pietrantoni C, Bhat A et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003 Jun 15;167 (12):1650–4.
  85. Saito A, Kohno S, Matsushima T et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother. 2006 Apr;12 (2):63–9.
  86. Gutiérrez F, Masiá M, Mirete C et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006 Sep;53 (3):166–74.
  87. Kothe H, Bauer T, Marre R et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008 Jul;32 (1):139–46.
  88. Юдина Л. В. Антибактериальная терапия при внегоспитальной пневмонии у пациентов пожилого и старческого возраста: акценты на главном. Украинский пульмонологический журнал. 2012;1:52–6.
  89. Strålin K, Olcén P, Törnqvist E, Holmberg H. Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores. Scand J Infect Dis. 2010 Jul;42 (6–7):426–34.
  90. Garcia-Vidal C, Carratalà J, Fernández-Sabé N et al. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect. 2009 Nov;15 (11):1033–8.
  91. Tudose C, Bumbăcea D, Bogdan M; Grupului BACTRO. Antibiotic resistance of S. pneumoniae and H. influenzae strains isolated from patients with community acquired respiratory tract infections. BACTRO multicenter, multidisciplinary study. Pneumologia. 2011 Jan-Mar;60 (1):30–5.
  92. Vallès X, Marcos A, Pinart M et al. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Chest. 2006 Sep;130 (3):800–6.
  93. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010 Dec 15;51 (12):1395–405.
  94. Restrepo MI, Mortensen EM, Velez JA et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008 Mar;133 (3):610–7.
  95. Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis. 2011 Aug;43 (8):609–15.
  96. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011 Nov;17 (Suppl 6):E1–59.
  97. Dambrava PG, Torres A, Vallès X et al. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J. 2008 Oct;32 (4):892–901.
  98. Orrick JJ, Segal R, Johns TE et al. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines. Pharmacoeconomics. 2004;22 (11):751–7.
  99. Merchant S, Mullins CD, Shih YC. Factors associated with hospitalization costs for patients with community-acquired pneumonia. Clin Ther. 2003 Feb;25 (2):593–610.
  100. Brown PD. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care? Pharmacoeconomics. 2004;22 (7):413–20.
Arutyunov A.G., Rylova A.K., Arutyunov G.P. Pneumonia in hospitalized patients with circulatory decompensation (Pavlov Hospital Registry). Russian Heart Failure Journal. 2014;84 (3):146–159

To access this material please log in or register

Register Authorize
Ru En